Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dr.Reddy's Laboratories Ltd Announces Approval of Azacitidine for Injection


Tuesday, 17 Sep 2013 02:13am EDT 

Dr.Reddy's Laboratories Ltd announced that Azacitidine for injection 100 mg/vial, a bioequivalent generic version of VIDAZA is approved by the USFDA on September 16, 2013. 

Company Quote

53.17
-0.28 -0.52%
6 May 2015